Tuncturk M, Kushwaha S, Heider R, Heider BS R, Oesterle T, Weinshilboum R
Int J Neuropsychopharmacol. 2025; 28(2).
PMID: 39831679
PMC: 11792077.
DOI: 10.1093/ijnp/pyaf005.
Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M
Int J Mol Sci. 2024; 25(14).
PMID: 39063024
PMC: 11277321.
DOI: 10.3390/ijms25147781.
Lu T, Li X, Zheng W, Kuang C, Wu B, Liu X
Pharmaceutics. 2024; 16(1).
PMID: 38258095
PMC: 10820210.
DOI: 10.3390/pharmaceutics16010084.
Shafieichaharberoud F, Lang S, Whalen C, Rivera Quiles C, Purcell L, Talbot C
Bioconjug Chem. 2023; 35(2):164-173.
PMID: 38113481
PMC: 11259974.
DOI: 10.1021/acs.bioconjchem.3c00415.
Hossain M, Davidson M, Kypreos E, Feehan J, Muir J, Nurgali K
Vaccines (Basel). 2022; 10(11).
PMID: 36366287
PMC: 9697687.
DOI: 10.3390/vaccines10111778.
Development of an Effective Monoclonal Antibody against Heroin and Its Metabolites Reveals Therapies Have Mistargeted 6-Monoacetylmorphine and Morphine over Heroin.
Lee J, Eubanks L, Zhou B, Janda K
ACS Cent Sci. 2022; 8(10):1464-1470.
PMID: 36313156
PMC: 9615117.
DOI: 10.1021/acscentsci.2c00977.
A Rapid Method for Direct Quantification of Antibody Binding-Site Concentration in Serum.
Abucayon E, Whalen C, Torres O, Duval A, Sulima A, Antoline J
ACS Omega. 2022; 7(30):26812-26823.
PMID: 35936462
PMC: 9352236.
DOI: 10.1021/acsomega.2c03237.
Calix[]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.
Da Silva Neto L, da Silva Maia A, Godin A, Augusto P, Lima Goncalves Pereira R, Caligiorne S
J Adv Res. 2022; 38:285-298.
PMID: 35572397
PMC: 9091763.
DOI: 10.1016/j.jare.2021.09.003.
Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats.
Crouse B, Zhang L, Robinson C, Ban Y, Vigliaturo J, Roy S
Hum Vaccin Immunother. 2021; 17(11):4383-4392.
PMID: 34411500
PMC: 8828096.
DOI: 10.1080/21645515.2021.1954442.
Synthesis and immunological effects of C14-linked 4,5-epoxymorphinan analogues as novel heroin vaccine haptens.
Gutman E, Irvin T, Morgan J, Barrientos R, Torres O, Beck Z
RSC Chem Biol. 2021; 2(3):835-842.
PMID: 34179783
PMC: 8190897.
DOI: 10.1039/d1cb00029b.
Synergistic immune and antinociceptive effects induced from the combination of two different vaccines against morphine/heroin in mouse.
Barbosa-Mendez S, Matus-Ortega M, Hernandez-Miramontes R, Salazar-Juarez A
Hum Vaccin Immunother. 2021; 17(10):3515-3528.
PMID: 34170784
PMC: 8437472.
DOI: 10.1080/21645515.2021.1935171.
Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.
Raleigh M, King S, Baruffaldi F, Saykao A, Hamid F, Winston S
Neuropharmacology. 2021; 195:108653.
PMID: 34126123
PMC: 8410661.
DOI: 10.1016/j.neuropharm.2021.108653.
A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys.
Townsend E, Bremer P, Jacob N, Negus S, Janda K, Banks M
Drug Alcohol Depend. 2020; 218:108348.
PMID: 33268227
PMC: 8224470.
DOI: 10.1016/j.drugalcdep.2020.108348.
Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity.
Robinson C, Gradinati V, Hamid F, Baehr C, Crouse B, Averick S
J Med Chem. 2020; 63(23):14647-14667.
PMID: 33215913
PMC: 8193686.
DOI: 10.1021/acs.jmedchem.0c01042.
Emerging Concepts and Technologies in Vaccine Development.
Brisse M, Vrba S, Kirk N, Liang Y, Ly H
Front Immunol. 2020; 11:583077.
PMID: 33101309
PMC: 7554600.
DOI: 10.3389/fimmu.2020.583077.
Synthesis of Potential Haptens with Morphine Skeleton and Determination of Protonation Constants.
Koteles I, Mazak K, Toth G, Tuz B, Hosztafi S
Molecules. 2020; 25(17).
PMID: 32887468
PMC: 7504778.
DOI: 10.3390/molecules25174009.
Sulfonate-isosteric replacement examined within heroin-hapten vaccine design.
Belz T, Bremer P, Zhou B, Blake S, Ellis B, Eubanks L
Bioorg Med Chem Lett. 2020; 30(17):127388.
PMID: 32738981
PMC: 7398700.
DOI: 10.1016/j.bmcl.2020.127388.
Enhancement of a Heroin Vaccine through Hapten Deuteration.
Belz T, Bremer P, Zhou B, Ellis B, Eubanks L, Janda K
J Am Chem Soc. 2020; 142(31):13294-13298.
PMID: 32700530
PMC: 7544008.
DOI: 10.1021/jacs.0c05219.
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
Raleigh M, Accetturo C, Pravetoni M
J Pharmacol Exp Ther. 2020; 374(3):392-403.
PMID: 32586850
PMC: 7430456.
DOI: 10.1124/jpet.120.000014.
Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity.
Gradinati V, Baruffaldi F, Abbaraju S, Laudenbach M, Amin R, Gilger B
Vaccine. 2020; 38(30):4704-4712.
PMID: 32439214
PMC: 8268746.
DOI: 10.1016/j.vaccine.2020.05.027.